Zai Lab and argenx Report Positive ALKIVIA Phase 3 Results
SHANGHAI, China / CAMBRIDGE, Massachusetts / AMSTERDAM, Netherlands — August 17, 2026 Zai Lab Limited and argenx announced positive...
efgartigimod
Advertisement
argenx Reports Positive Phase 3 ALKIVIA Myositis Results
Amsterdam, Netherlands, August 17, 2026 argenx SE announced positive topline results from the Phase 3 ALKIVIA study evaluating VYVGART...
argenx Reports Long-Term Efgartigimod Benefits in Myositis and Sjogren’s Disease at EULAR 2026
AMSTERDAM, Netherlands, June 3, 2026 argenx presented new clinical data at the European Alliance of Associations for Rheumatology (EULAR)...
Argenx Gains FDA Approval Expanding VYVGART to All gMG Patients
AMSTERDAM, Netherlands, May 8, 2026 Argenx SE announced that the U.S. Food and Drug Administration (FDA) has approved a...
Advertisement
